nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—Etoposide—testicular cancer	0.269	0.447	CbGbCtD
Naltrexone—ABCB1—Dactinomycin—testicular cancer	0.0945	0.157	CbGbCtD
Naltrexone—ABCB1—Vinblastine—testicular cancer	0.0592	0.0984	CbGbCtD
Naltrexone—ABCB1—Cisplatin—testicular cancer	0.0543	0.0902	CbGbCtD
Naltrexone—ABCB1—Etoposide—testicular cancer	0.0533	0.0886	CbGbCtD
Naltrexone—ABCB1—Doxorubicin—testicular cancer	0.0364	0.0604	CbGbCtD
Naltrexone—ABCB1—Methotrexate—testicular cancer	0.0352	0.0586	CbGbCtD
Naltrexone—Bronchitis—Doxorubicin—testicular cancer	0.000374	0.000939	CcSEcCtD
Naltrexone—Rash—Dactinomycin—testicular cancer	0.000372	0.000933	CcSEcCtD
Naltrexone—Decreased appetite—Etoposide—testicular cancer	0.000371	0.000931	CcSEcCtD
Naltrexone—Diarrhoea—Ifosfamide—testicular cancer	0.000369	0.000927	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Etoposide—testicular cancer	0.000368	0.000924	CcSEcCtD
Naltrexone—Body temperature increased—Cisplatin—testicular cancer	0.000368	0.000924	CcSEcCtD
Naltrexone—Fatigue—Etoposide—testicular cancer	0.000368	0.000923	CcSEcCtD
Naltrexone—Constipation—Etoposide—testicular cancer	0.000365	0.000915	CcSEcCtD
Naltrexone—Pain—Etoposide—testicular cancer	0.000365	0.000915	CcSEcCtD
Naltrexone—Conjunctivitis—Epirubicin—testicular cancer	0.000364	0.000915	CcSEcCtD
Naltrexone—Urinary tract infection—Epirubicin—testicular cancer	0.000364	0.000915	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000362	0.000907	CcSEcCtD
Naltrexone—Hepatitis—Methotrexate—testicular cancer	0.00036	0.000903	CcSEcCtD
Naltrexone—Dizziness—Ifosfamide—testicular cancer	0.000357	0.000896	CcSEcCtD
Naltrexone—Pharyngitis—Methotrexate—testicular cancer	0.000357	0.000896	CcSEcCtD
Naltrexone—Hepatobiliary disease—Epirubicin—testicular cancer	0.000355	0.00089	CcSEcCtD
Naltrexone—Weight increased—Doxorubicin—testicular cancer	0.000354	0.000889	CcSEcCtD
Naltrexone—Epistaxis—Epirubicin—testicular cancer	0.000354	0.000887	CcSEcCtD
Naltrexone—Weight decreased—Doxorubicin—testicular cancer	0.000352	0.000883	CcSEcCtD
Naltrexone—Sinusitis—Epirubicin—testicular cancer	0.000352	0.000883	CcSEcCtD
Naltrexone—Feeling abnormal—Etoposide—testicular cancer	0.000351	0.000882	CcSEcCtD
Naltrexone—Nausea—Dactinomycin—testicular cancer	0.00035	0.000879	CcSEcCtD
Naltrexone—Pneumonia—Doxorubicin—testicular cancer	0.000349	0.000876	CcSEcCtD
Naltrexone—Gastrointestinal pain—Etoposide—testicular cancer	0.000349	0.000875	CcSEcCtD
Naltrexone—Infestation NOS—Doxorubicin—testicular cancer	0.000347	0.000871	CcSEcCtD
Naltrexone—Infestation—Doxorubicin—testicular cancer	0.000347	0.000871	CcSEcCtD
Naltrexone—Vomiting—Ifosfamide—testicular cancer	0.000343	0.000862	CcSEcCtD
Naltrexone—Hypersensitivity—Cisplatin—testicular cancer	0.000343	0.000861	CcSEcCtD
Naltrexone—Rash—Ifosfamide—testicular cancer	0.00034	0.000855	CcSEcCtD
Naltrexone—Dermatitis—Ifosfamide—testicular cancer	0.00034	0.000854	CcSEcCtD
Naltrexone—Urticaria—Etoposide—testicular cancer	0.000339	0.00085	CcSEcCtD
Naltrexone—Abdominal pain—Etoposide—testicular cancer	0.000337	0.000846	CcSEcCtD
Naltrexone—Body temperature increased—Etoposide—testicular cancer	0.000337	0.000846	CcSEcCtD
Naltrexone—Conjunctivitis—Doxorubicin—testicular cancer	0.000337	0.000846	CcSEcCtD
Naltrexone—Urinary tract infection—Doxorubicin—testicular cancer	0.000337	0.000846	CcSEcCtD
Naltrexone—Hepatitis—Epirubicin—testicular cancer	0.000337	0.000845	CcSEcCtD
Naltrexone—Eye disorder—Methotrexate—testicular cancer	0.000336	0.000843	CcSEcCtD
Naltrexone—Tinnitus—Methotrexate—testicular cancer	0.000335	0.000841	CcSEcCtD
Naltrexone—Asthenia—Cisplatin—testicular cancer	0.000334	0.000838	CcSEcCtD
Naltrexone—Pharyngitis—Epirubicin—testicular cancer	0.000334	0.000838	CcSEcCtD
Naltrexone—Cardiac disorder—Methotrexate—testicular cancer	0.000334	0.000838	CcSEcCtD
Naltrexone—Connective tissue disorder—Epirubicin—testicular cancer	0.000331	0.00083	CcSEcCtD
Naltrexone—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000328	0.000823	CcSEcCtD
Naltrexone—Epistaxis—Doxorubicin—testicular cancer	0.000327	0.000821	CcSEcCtD
Naltrexone—Angiopathy—Methotrexate—testicular cancer	0.000326	0.000819	CcSEcCtD
Naltrexone—Sinusitis—Doxorubicin—testicular cancer	0.000325	0.000817	CcSEcCtD
Naltrexone—Immune system disorder—Methotrexate—testicular cancer	0.000325	0.000815	CcSEcCtD
Naltrexone—Mediastinal disorder—Methotrexate—testicular cancer	0.000324	0.000813	CcSEcCtD
Naltrexone—Chills—Methotrexate—testicular cancer	0.000323	0.00081	CcSEcCtD
Naltrexone—Nausea—Ifosfamide—testicular cancer	0.000321	0.000805	CcSEcCtD
Naltrexone—Diarrhoea—Cisplatin—testicular cancer	0.000319	0.0008	CcSEcCtD
Naltrexone—Alopecia—Methotrexate—testicular cancer	0.000318	0.000798	CcSEcCtD
Naltrexone—Mental disorder—Methotrexate—testicular cancer	0.000315	0.000791	CcSEcCtD
Naltrexone—Eye disorder—Epirubicin—testicular cancer	0.000314	0.000789	CcSEcCtD
Naltrexone—Hypersensitivity—Etoposide—testicular cancer	0.000314	0.000789	CcSEcCtD
Naltrexone—Tinnitus—Epirubicin—testicular cancer	0.000314	0.000788	CcSEcCtD
Naltrexone—Malnutrition—Methotrexate—testicular cancer	0.000313	0.000786	CcSEcCtD
Naltrexone—Cardiac disorder—Epirubicin—testicular cancer	0.000312	0.000784	CcSEcCtD
Naltrexone—Hepatitis—Doxorubicin—testicular cancer	0.000311	0.000782	CcSEcCtD
Naltrexone—Pharyngitis—Doxorubicin—testicular cancer	0.000309	0.000776	CcSEcCtD
Naltrexone—Dysgeusia—Methotrexate—testicular cancer	0.000307	0.000769	CcSEcCtD
Naltrexone—Asthenia—Etoposide—testicular cancer	0.000306	0.000768	CcSEcCtD
Naltrexone—Connective tissue disorder—Doxorubicin—testicular cancer	0.000306	0.000768	CcSEcCtD
Naltrexone—Angiopathy—Epirubicin—testicular cancer	0.000305	0.000766	CcSEcCtD
Naltrexone—Immune system disorder—Epirubicin—testicular cancer	0.000304	0.000763	CcSEcCtD
Naltrexone—Mediastinal disorder—Epirubicin—testicular cancer	0.000303	0.000761	CcSEcCtD
Naltrexone—Back pain—Methotrexate—testicular cancer	0.000303	0.00076	CcSEcCtD
Naltrexone—Chills—Epirubicin—testicular cancer	0.000302	0.000758	CcSEcCtD
Naltrexone—Pruritus—Etoposide—testicular cancer	0.000302	0.000757	CcSEcCtD
Naltrexone—Alopecia—Epirubicin—testicular cancer	0.000297	0.000746	CcSEcCtD
Naltrexone—Vomiting—Cisplatin—testicular cancer	0.000296	0.000743	CcSEcCtD
Naltrexone—Vision blurred—Methotrexate—testicular cancer	0.000295	0.00074	CcSEcCtD
Naltrexone—Mental disorder—Epirubicin—testicular cancer	0.000295	0.00074	CcSEcCtD
Naltrexone—Rash—Cisplatin—testicular cancer	0.000294	0.000737	CcSEcCtD
Naltrexone—Dermatitis—Cisplatin—testicular cancer	0.000293	0.000736	CcSEcCtD
Naltrexone—Malnutrition—Epirubicin—testicular cancer	0.000293	0.000735	CcSEcCtD
Naltrexone—Diarrhoea—Etoposide—testicular cancer	0.000292	0.000732	CcSEcCtD
Naltrexone—Eye disorder—Doxorubicin—testicular cancer	0.000291	0.00073	CcSEcCtD
Naltrexone—Ill-defined disorder—Methotrexate—testicular cancer	0.00029	0.000729	CcSEcCtD
Naltrexone—Tinnitus—Doxorubicin—testicular cancer	0.00029	0.000729	CcSEcCtD
Naltrexone—Cardiac disorder—Doxorubicin—testicular cancer	0.000289	0.000725	CcSEcCtD
Naltrexone—Flatulence—Epirubicin—testicular cancer	0.000289	0.000725	CcSEcCtD
Naltrexone—Tension—Epirubicin—testicular cancer	0.000287	0.000722	CcSEcCtD
Naltrexone—Dysgeusia—Epirubicin—testicular cancer	0.000287	0.00072	CcSEcCtD
Naltrexone—Nervousness—Epirubicin—testicular cancer	0.000285	0.000714	CcSEcCtD
Naltrexone—Back pain—Epirubicin—testicular cancer	0.000283	0.000711	CcSEcCtD
Naltrexone—Angiopathy—Doxorubicin—testicular cancer	0.000283	0.000709	CcSEcCtD
Naltrexone—Malaise—Methotrexate—testicular cancer	0.000282	0.000709	CcSEcCtD
Naltrexone—Dizziness—Etoposide—testicular cancer	0.000282	0.000708	CcSEcCtD
Naltrexone—Muscle spasms—Epirubicin—testicular cancer	0.000282	0.000707	CcSEcCtD
Naltrexone—Immune system disorder—Doxorubicin—testicular cancer	0.000281	0.000706	CcSEcCtD
Naltrexone—Mediastinal disorder—Doxorubicin—testicular cancer	0.000281	0.000704	CcSEcCtD
Naltrexone—Chills—Doxorubicin—testicular cancer	0.000279	0.000701	CcSEcCtD
Naltrexone—Nausea—Cisplatin—testicular cancer	0.000277	0.000694	CcSEcCtD
Naltrexone—Vision blurred—Epirubicin—testicular cancer	0.000276	0.000693	CcSEcCtD
Naltrexone—Alopecia—Doxorubicin—testicular cancer	0.000275	0.000691	CcSEcCtD
Naltrexone—Cough—Methotrexate—testicular cancer	0.000273	0.000686	CcSEcCtD
Naltrexone—Mental disorder—Doxorubicin—testicular cancer	0.000273	0.000685	CcSEcCtD
Naltrexone—Ill-defined disorder—Epirubicin—testicular cancer	0.000272	0.000682	CcSEcCtD
Naltrexone—Convulsion—Methotrexate—testicular cancer	0.000271	0.000681	CcSEcCtD
Naltrexone—Vomiting—Etoposide—testicular cancer	0.000271	0.000681	CcSEcCtD
Naltrexone—Malnutrition—Doxorubicin—testicular cancer	0.000271	0.00068	CcSEcCtD
Naltrexone—Agitation—Epirubicin—testicular cancer	0.000269	0.000676	CcSEcCtD
Naltrexone—Rash—Etoposide—testicular cancer	0.000269	0.000675	CcSEcCtD
Naltrexone—Dermatitis—Etoposide—testicular cancer	0.000269	0.000674	CcSEcCtD
Naltrexone—Headache—Etoposide—testicular cancer	0.000267	0.000671	CcSEcCtD
Naltrexone—Flatulence—Doxorubicin—testicular cancer	0.000267	0.00067	CcSEcCtD
Naltrexone—Arthralgia—Methotrexate—testicular cancer	0.000266	0.000669	CcSEcCtD
Naltrexone—Myalgia—Methotrexate—testicular cancer	0.000266	0.000669	CcSEcCtD
Naltrexone—Chest pain—Methotrexate—testicular cancer	0.000266	0.000669	CcSEcCtD
Naltrexone—Tension—Doxorubicin—testicular cancer	0.000266	0.000668	CcSEcCtD
Naltrexone—Dysgeusia—Doxorubicin—testicular cancer	0.000265	0.000666	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000265	0.000664	CcSEcCtD
Naltrexone—Malaise—Epirubicin—testicular cancer	0.000264	0.000663	CcSEcCtD
Naltrexone—Discomfort—Methotrexate—testicular cancer	0.000263	0.000661	CcSEcCtD
Naltrexone—Nervousness—Doxorubicin—testicular cancer	0.000263	0.000661	CcSEcCtD
Naltrexone—Syncope—Epirubicin—testicular cancer	0.000263	0.000659	CcSEcCtD
Naltrexone—Back pain—Doxorubicin—testicular cancer	0.000262	0.000658	CcSEcCtD
Naltrexone—Muscle spasms—Doxorubicin—testicular cancer	0.000261	0.000654	CcSEcCtD
Naltrexone—Palpitations—Epirubicin—testicular cancer	0.000259	0.00065	CcSEcCtD
Naltrexone—Confusional state—Methotrexate—testicular cancer	0.000258	0.000647	CcSEcCtD
Naltrexone—Loss of consciousness—Epirubicin—testicular cancer	0.000257	0.000646	CcSEcCtD
Naltrexone—Cough—Epirubicin—testicular cancer	0.000256	0.000642	CcSEcCtD
Naltrexone—Anaphylactic shock—Methotrexate—testicular cancer	0.000255	0.000641	CcSEcCtD
Naltrexone—Vision blurred—Doxorubicin—testicular cancer	0.000255	0.000641	CcSEcCtD
Naltrexone—Convulsion—Epirubicin—testicular cancer	0.000254	0.000637	CcSEcCtD
Naltrexone—Infection—Methotrexate—testicular cancer	0.000254	0.000637	CcSEcCtD
Naltrexone—Nausea—Etoposide—testicular cancer	0.000253	0.000636	CcSEcCtD
Naltrexone—Hypertension—Epirubicin—testicular cancer	0.000253	0.000635	CcSEcCtD
Naltrexone—Ill-defined disorder—Doxorubicin—testicular cancer	0.000251	0.000631	CcSEcCtD
Naltrexone—Nervous system disorder—Methotrexate—testicular cancer	0.000251	0.000629	CcSEcCtD
Naltrexone—Chest pain—Epirubicin—testicular cancer	0.000249	0.000626	CcSEcCtD
Naltrexone—Myalgia—Epirubicin—testicular cancer	0.000249	0.000626	CcSEcCtD
Naltrexone—Arthralgia—Epirubicin—testicular cancer	0.000249	0.000626	CcSEcCtD
Naltrexone—Agitation—Doxorubicin—testicular cancer	0.000249	0.000625	CcSEcCtD
Naltrexone—Anxiety—Epirubicin—testicular cancer	0.000249	0.000624	CcSEcCtD
Naltrexone—Skin disorder—Methotrexate—testicular cancer	0.000248	0.000623	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000248	0.000622	CcSEcCtD
Naltrexone—Hyperhidrosis—Methotrexate—testicular cancer	0.000247	0.00062	CcSEcCtD
Naltrexone—Discomfort—Epirubicin—testicular cancer	0.000246	0.000618	CcSEcCtD
Naltrexone—Malaise—Doxorubicin—testicular cancer	0.000244	0.000614	CcSEcCtD
Naltrexone—Dry mouth—Epirubicin—testicular cancer	0.000244	0.000612	CcSEcCtD
Naltrexone—Anorexia—Methotrexate—testicular cancer	0.000244	0.000611	CcSEcCtD
Naltrexone—Syncope—Doxorubicin—testicular cancer	0.000243	0.00061	CcSEcCtD
Naltrexone—Confusional state—Epirubicin—testicular cancer	0.000241	0.000605	CcSEcCtD
Naltrexone—Palpitations—Doxorubicin—testicular cancer	0.00024	0.000601	CcSEcCtD
Naltrexone—Anaphylactic shock—Epirubicin—testicular cancer	0.000239	0.0006	CcSEcCtD
Naltrexone—Oedema—Epirubicin—testicular cancer	0.000239	0.0006	CcSEcCtD
Naltrexone—Loss of consciousness—Doxorubicin—testicular cancer	0.000238	0.000598	CcSEcCtD
Naltrexone—Infection—Epirubicin—testicular cancer	0.000238	0.000596	CcSEcCtD
Naltrexone—Cough—Doxorubicin—testicular cancer	0.000237	0.000594	CcSEcCtD
Naltrexone—Shock—Epirubicin—testicular cancer	0.000235	0.00059	CcSEcCtD
Naltrexone—Convulsion—Doxorubicin—testicular cancer	0.000235	0.000589	CcSEcCtD
Naltrexone—Nervous system disorder—Epirubicin—testicular cancer	0.000234	0.000588	CcSEcCtD
Naltrexone—Hypertension—Doxorubicin—testicular cancer	0.000234	0.000587	CcSEcCtD
Naltrexone—Tachycardia—Epirubicin—testicular cancer	0.000233	0.000586	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000233	0.000584	CcSEcCtD
Naltrexone—Skin disorder—Epirubicin—testicular cancer	0.000232	0.000583	CcSEcCtD
Naltrexone—Hyperhidrosis—Epirubicin—testicular cancer	0.000231	0.00058	CcSEcCtD
Naltrexone—Insomnia—Methotrexate—testicular cancer	0.000231	0.00058	CcSEcCtD
Naltrexone—Myalgia—Doxorubicin—testicular cancer	0.000231	0.000579	CcSEcCtD
Naltrexone—Arthralgia—Doxorubicin—testicular cancer	0.000231	0.000579	CcSEcCtD
Naltrexone—Chest pain—Doxorubicin—testicular cancer	0.000231	0.000579	CcSEcCtD
Naltrexone—Anxiety—Doxorubicin—testicular cancer	0.00023	0.000577	CcSEcCtD
Naltrexone—Paraesthesia—Methotrexate—testicular cancer	0.000229	0.000576	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000229	0.000575	CcSEcCtD
Naltrexone—Discomfort—Doxorubicin—testicular cancer	0.000228	0.000572	CcSEcCtD
Naltrexone—Anorexia—Epirubicin—testicular cancer	0.000228	0.000572	CcSEcCtD
Naltrexone—Dyspnoea—Methotrexate—testicular cancer	0.000228	0.000572	CcSEcCtD
Naltrexone—Somnolence—Methotrexate—testicular cancer	0.000227	0.00057	CcSEcCtD
Naltrexone—Dry mouth—Doxorubicin—testicular cancer	0.000226	0.000566	CcSEcCtD
Naltrexone—Confusional state—Doxorubicin—testicular cancer	0.000223	0.00056	CcSEcCtD
Naltrexone—Decreased appetite—Methotrexate—testicular cancer	0.000222	0.000557	CcSEcCtD
Naltrexone—Oedema—Doxorubicin—testicular cancer	0.000221	0.000555	CcSEcCtD
Naltrexone—Anaphylactic shock—Doxorubicin—testicular cancer	0.000221	0.000555	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000221	0.000554	CcSEcCtD
Naltrexone—Fatigue—Methotrexate—testicular cancer	0.00022	0.000553	CcSEcCtD
Naltrexone—Infection—Doxorubicin—testicular cancer	0.00022	0.000552	CcSEcCtD
Naltrexone—Pain—Methotrexate—testicular cancer	0.000218	0.000548	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000218	0.000547	CcSEcCtD
Naltrexone—Shock—Doxorubicin—testicular cancer	0.000218	0.000546	CcSEcCtD
Naltrexone—Nervous system disorder—Doxorubicin—testicular cancer	0.000217	0.000545	CcSEcCtD
Naltrexone—Insomnia—Epirubicin—testicular cancer	0.000216	0.000543	CcSEcCtD
Naltrexone—Tachycardia—Doxorubicin—testicular cancer	0.000216	0.000542	CcSEcCtD
Naltrexone—Skin disorder—Doxorubicin—testicular cancer	0.000215	0.000539	CcSEcCtD
Naltrexone—Paraesthesia—Epirubicin—testicular cancer	0.000215	0.000539	CcSEcCtD
Naltrexone—Hyperhidrosis—Doxorubicin—testicular cancer	0.000214	0.000537	CcSEcCtD
Naltrexone—Dyspnoea—Epirubicin—testicular cancer	0.000213	0.000535	CcSEcCtD
Naltrexone—Somnolence—Epirubicin—testicular cancer	0.000213	0.000533	CcSEcCtD
Naltrexone—Anorexia—Doxorubicin—testicular cancer	0.000211	0.000529	CcSEcCtD
Naltrexone—Feeling abnormal—Methotrexate—testicular cancer	0.000211	0.000528	CcSEcCtD
Naltrexone—Gastrointestinal pain—Methotrexate—testicular cancer	0.000209	0.000524	CcSEcCtD
Naltrexone—Decreased appetite—Epirubicin—testicular cancer	0.000208	0.000522	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000206	0.000518	CcSEcCtD
Naltrexone—Fatigue—Epirubicin—testicular cancer	0.000206	0.000517	CcSEcCtD
Naltrexone—Pain—Epirubicin—testicular cancer	0.000204	0.000513	CcSEcCtD
Naltrexone—Constipation—Epirubicin—testicular cancer	0.000204	0.000513	CcSEcCtD
Naltrexone—Urticaria—Methotrexate—testicular cancer	0.000203	0.000509	CcSEcCtD
Naltrexone—Body temperature increased—Methotrexate—testicular cancer	0.000202	0.000507	CcSEcCtD
Naltrexone—Abdominal pain—Methotrexate—testicular cancer	0.000202	0.000507	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000202	0.000506	CcSEcCtD
Naltrexone—Insomnia—Doxorubicin—testicular cancer	0.0002	0.000502	CcSEcCtD
Naltrexone—Paraesthesia—Doxorubicin—testicular cancer	0.000199	0.000499	CcSEcCtD
Naltrexone—Dyspnoea—Doxorubicin—testicular cancer	0.000197	0.000495	CcSEcCtD
Naltrexone—Feeling abnormal—Epirubicin—testicular cancer	0.000197	0.000494	CcSEcCtD
Naltrexone—Somnolence—Doxorubicin—testicular cancer	0.000197	0.000494	CcSEcCtD
Naltrexone—Gastrointestinal pain—Epirubicin—testicular cancer	0.000196	0.000491	CcSEcCtD
Naltrexone—Decreased appetite—Doxorubicin—testicular cancer	0.000192	0.000483	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000191	0.000479	CcSEcCtD
Naltrexone—Fatigue—Doxorubicin—testicular cancer	0.000191	0.000479	CcSEcCtD
Naltrexone—Urticaria—Epirubicin—testicular cancer	0.00019	0.000477	CcSEcCtD
Naltrexone—Constipation—Doxorubicin—testicular cancer	0.000189	0.000475	CcSEcCtD
Naltrexone—Pain—Doxorubicin—testicular cancer	0.000189	0.000475	CcSEcCtD
Naltrexone—Abdominal pain—Epirubicin—testicular cancer	0.000189	0.000474	CcSEcCtD
Naltrexone—Body temperature increased—Epirubicin—testicular cancer	0.000189	0.000474	CcSEcCtD
Naltrexone—Hypersensitivity—Methotrexate—testicular cancer	0.000188	0.000472	CcSEcCtD
Naltrexone—Asthenia—Methotrexate—testicular cancer	0.000183	0.00046	CcSEcCtD
Naltrexone—Feeling abnormal—Doxorubicin—testicular cancer	0.000182	0.000458	CcSEcCtD
Naltrexone—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000181	0.000454	CcSEcCtD
Naltrexone—Pruritus—Methotrexate—testicular cancer	0.000181	0.000454	CcSEcCtD
Naltrexone—Hypersensitivity—Epirubicin—testicular cancer	0.000176	0.000442	CcSEcCtD
Naltrexone—Urticaria—Doxorubicin—testicular cancer	0.000176	0.000441	CcSEcCtD
Naltrexone—Abdominal pain—Doxorubicin—testicular cancer	0.000175	0.000439	CcSEcCtD
Naltrexone—Body temperature increased—Doxorubicin—testicular cancer	0.000175	0.000439	CcSEcCtD
Naltrexone—Diarrhoea—Methotrexate—testicular cancer	0.000175	0.000439	CcSEcCtD
Naltrexone—Asthenia—Epirubicin—testicular cancer	0.000172	0.000431	CcSEcCtD
Naltrexone—Pruritus—Epirubicin—testicular cancer	0.000169	0.000425	CcSEcCtD
Naltrexone—Dizziness—Methotrexate—testicular cancer	0.000169	0.000424	CcSEcCtD
Naltrexone—Diarrhoea—Epirubicin—testicular cancer	0.000164	0.000411	CcSEcCtD
Naltrexone—Hypersensitivity—Doxorubicin—testicular cancer	0.000163	0.000409	CcSEcCtD
Naltrexone—Vomiting—Methotrexate—testicular cancer	0.000162	0.000408	CcSEcCtD
Naltrexone—Rash—Methotrexate—testicular cancer	0.000161	0.000404	CcSEcCtD
Naltrexone—Dermatitis—Methotrexate—testicular cancer	0.000161	0.000404	CcSEcCtD
Naltrexone—Headache—Methotrexate—testicular cancer	0.00016	0.000402	CcSEcCtD
Naltrexone—Asthenia—Doxorubicin—testicular cancer	0.000159	0.000398	CcSEcCtD
Naltrexone—Dizziness—Epirubicin—testicular cancer	0.000158	0.000397	CcSEcCtD
Naltrexone—Pruritus—Doxorubicin—testicular cancer	0.000157	0.000393	CcSEcCtD
Naltrexone—Vomiting—Epirubicin—testicular cancer	0.000152	0.000382	CcSEcCtD
Naltrexone—Nausea—Methotrexate—testicular cancer	0.000152	0.000381	CcSEcCtD
Naltrexone—Diarrhoea—Doxorubicin—testicular cancer	0.000151	0.00038	CcSEcCtD
Naltrexone—Rash—Epirubicin—testicular cancer	0.000151	0.000378	CcSEcCtD
Naltrexone—Dermatitis—Epirubicin—testicular cancer	0.000151	0.000378	CcSEcCtD
Naltrexone—Headache—Epirubicin—testicular cancer	0.00015	0.000376	CcSEcCtD
Naltrexone—Dizziness—Doxorubicin—testicular cancer	0.000146	0.000367	CcSEcCtD
Naltrexone—Nausea—Epirubicin—testicular cancer	0.000142	0.000356	CcSEcCtD
Naltrexone—Vomiting—Doxorubicin—testicular cancer	0.000141	0.000353	CcSEcCtD
Naltrexone—Rash—Doxorubicin—testicular cancer	0.000139	0.00035	CcSEcCtD
Naltrexone—Dermatitis—Doxorubicin—testicular cancer	0.000139	0.00035	CcSEcCtD
Naltrexone—Headache—Doxorubicin—testicular cancer	0.000139	0.000348	CcSEcCtD
Naltrexone—Nausea—Doxorubicin—testicular cancer	0.000131	0.00033	CcSEcCtD
